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Abstract
Background: Leprosy is the most frequent treatable neuromuscular disease. Yet, every year, thousands of patients develop
permanent peripheral nerve damage as a result of leprosy. Since early detection and treatment of neuropathy in leprosy has
strong preventive potential, we conducted a cohort study to determine which test detects this neuropathy earliest.
Methods and Findings: One hundred and eighty-eight multibacillary (MB) leprosy patients were selected from a cohort of
303 and followed for 2 years after diagnosis. Nerve function was evaluated at each visit using nerve conduction (NC),
quantitative thermal sensory testing and vibrometry, dynamometry, monofilament testing (MFT), and voluntary muscle
testing (VMT). Study outcomes were sensory and motor impairment detected by MFT or VMT. Seventy-four of 188 patients
(39%) had a reaction, neuritis, or new nerve function impairment (NFI) event during a 2-year follow-up. Sub-clinical
neuropathy was extensive (20%–50%), even in patients who did not develop an outcome event. Sensory nerve action
potential (SNAP) amplitudes, compound motor action potential (CMAP) velocities, and warm detection thresholds (WDT)
were most frequently affected, with SNAP impairment frequencies ranging from 30% (median) to 69% (sural). Velocity was
impaired in up to 43% of motor nerves. WDTs were more frequently affected than cold detection thresholds (29% versus
13%, ulnar nerve). Impairment of SNC and warm perception often preceded deterioration in MF or VMT scores by 12 weeks
or more.
Conclusions: A large proportion of leprosy patients have subclinical neuropathy that was not evident when only MFT and
VMT were used. SNC was the most frequently and earliest affected test, closely followed by WDT. They are promising tests
for improving early detection of neuropathy, as they often became abnormal 12 weeks or more before an abnormal
monofilament test. Changes in MFT and VMT score mirrored changes in neurophysiology, confirming their validity as
screening tests.
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Introduction
‘Early detection improves prognosis’ is a general axiom in
medicine, and in leprosy delay in detection is strongly associated
with an increased risk of neural impairment at diagnosis [1–4]. In
addition, nerve function impairment (NFI) already present at
diagnosis has been found to be a strong predictor of the risk of
further immunological reactions or episodes of sensory or motor
neuropathy [5–7]. Around 10% of the 300,000 new leprosy cases
registered every year have signs of sensory, motor or autonomic
neuropathy at diagnosis. The highest rates of impairment were
reported from Ethiopia (55%) [7], while studies in Thailand and
Bangladesh reported rates of 18% and 12%, respectively [4,8].
New neuropathy may develop both during and after effective
multi-drug therapy [9]. A substantial proportion of people with
leprosy-related nerve damage will have life-long functional and/or
social disability [10]. Early detection and treatment of NFI is
therefore seen as a top priority [11].
Assessment of sensory function of nerves affected by leprosy is
typically done with the monofilament test (MFT). This test uses
standardised, graded nylon monofilaments to monitor touch
sensation on the hand palms and foot soles semi-quantitatively
[12]. Motor function is monitored using the voluntary muscle test
(VMT) [13,14]. Both tests have been shown to be valid and
reliable under various conditions [15–17].
Nerve conduction (NC) testing has been done in leprosy
patients, but most studies were small and cross-sectional and
involved mixed groups of new and treated subjects [18–26].
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Ramakrishnan & Srinivasan tried to determine which electro-
physiological test would best discriminate between normal and
abnormal (median) nerve function in leprosy [24]. They found that
the amplitudes of the distal sensory nerve action potentials (SNAP)
were more reliable indicators of leprosy neuropathy than sensory
nerve conduction (SNC) velocities.
The only studies comparing different tests of nerve function
were those by Naafs & Dagne, Touw-Langendijk et al. and
Samant et al. [26–28]. They did not find advantage in motor
nerve conduction (MNC) over VMT or sensory testing with
monofilaments or a combination of the latter with nerve palpation.
Investigators in cross-sectional studies have concluded that NC
studies were very useful and would potentially detect pre-clinical
neuropathy [19,21,24,26].
Quantitative sensory testing (QST) has opened up new
possibilities for the study of sensory neuropathy [29,30]. The
most commonly used methods are thermal threshold testing and
testing of vibration perception thresholds. Thermal testing assesses
small, unmyelinated C-fibres that mediate warm sensation and
small, unmyelinated and myelinated Ad fibres mediating cold
sensation [31]. Like nerve conduction, vibrometry assesses large,
myelinated Ab fibres [32]. QST has been used only occasionally
and in cross-sectional studies [33,34]. Vibrometry did not appear
to have much additional advantage over more established methods
of sensory testing. Abbot et al. and Wilder-Smith et al. used laser
Doppler flowmetry for quantitative assessment of autonomic nerve
function [35–37]. This method appeared very sensitive and
detected widespread autonomic neuropathy in hands and feet of
leprosy patients [38].
The INFIR cohort is a group of newly diagnosed patients with
multibacillary leprosy (MB). They had monthly tests of nerve
function using MFT, VMT, nerve conduction studies, thermal
sensation and vibrometry. This cohort has enabled us to test the
hypothesis that monofilaments and VMT are relatively insensitive
methods for detecting nerve damage. Having a cohort of patients
has also enabled us to test the hypothesis that nerve damage occurs
over a long period and can be detected earlier if more sensitive
methods are employed.
Methods
Details of the methods have been published before [39]; only a
brief summary will be given here.
Design
A cohort study with 4-weekly follow-up for one year and 8-
weekly follow-up during the second year.
Study subjects
303 patients with MB leprosy, newly diagnosed at two referral
hospitals in Uttar Pradesh, India, were included in the cohort.
Patients who had a reaction or sensory or motor impairment at
diagnosis were excluded from this analysis. The study subjects
were at different stages of their disease, as reported earlier [39]. A
brief summary is given in the Results section below.
Outcome events
Outcome events for this analysis were sensory impairment (SI)
and motor impairment (MI), as detected by the MFT and VMT
(for definitions see Text S1). The techniques have been described
elsewhere [39]. ‘New impairment’ of a neurological parameter was
defined as ‘impairment which was not present at any earlier
follow-up visit’. Thresholds for impairment calculations are in the
Analysis section.
Outcome measures
Nerve function test results and outcome events.
1. Median values of test parameters
2. Percentage of patients testing positive (impaired) for
a given measure or marker.
Early detection of sensory or motor impairment.
3. Sensitivity and positive and negative predictive
value of each test in predicting clinically significant
NFI diagnosed with MFT or VMT
Examination and treatment
A standardised history using a checklist was taken from all
patients. All patients had a physical examination and a basic
neurological examination (including reflexes, joint position sense
and nerve palpation) on admission and repeated at each visit.
Evidence (signs and symptoms) of Type 1 Reaction (T1R),
Erythema Nodosum Leprosum (ENL) and peripheral neuropathy
was carefully sought.
Nerve function assessment (NFA)
The following techniques were used for measuring nerve
function at each follow-up visit.
Motor nerve function.
1. Voluntary muscle testing (VMT) using the 0–5
modified MRC scale [39].
2. Grip dynamometry, key pinch and pulp-to-pulp
pinch testing
A dynamometer was made of a sphygmomanometer cuff
inserted in a cylindrical cotton cover and inflated to a
baseline pressure of 20 mmHg. Pinch strength was
measured in a similar way using a neonatal sphygmo-
manometer cuff [40].
3. Motor nerve conduction measurements
(MNC)
Author Summary
Leprosy is the most frequent treatable disease of the
peripheral nerves. Yet, every year, thousands of patients
develop nerve damage as a result of leprosy. If this is
detected and treated early, the prognosis is good. We
conducted the largest prospective study on this topic to
date to determine which test would detect nerve damage
earliest. One hundred and eighty-eight leprosy patients
were selected from centres in North India and followed for
2 years after diagnosis. Nerve function was tested at each
visit using a battery of nerve function tests. A large
proportion of the patients had or developed subclinical
nerve damage that was not detected with the standard
clinical tests (monofilaments and voluntary muscle test-
ing). Sensory nerve conduction was the most frequently
and earliest affected test, closely followed by the warm
temperature perception test. They are promising tests for
improving early detection of nerve damage, as they often
became abnormal 12 weeks or more before the monofil-
ament test became abnormal. Changes measured with the
monofilament and voluntary muscle tests mirrored chang-
es in more advanced electronic measures, confirming their
validity as screening tests. These findings open the door to
future improvement of the prognosis of nerve damage in
leprosy.
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Nerve conduction parameters were measured using
Neurocare 2000H EMG machines (BioTech Ltd.,
Mumbai). The testing room was maintained at around
26uC (confirmed using ambient thermometers). Patients
were allowed to acclimatise for 15 minutes before
testing. Monopolar surface recording electrodes and
bipolar hand held stimulating electrodes were used to
obtain the compound muscle action potentials (CMAP).
All motor tests used the belly-tendon method. The
calculated values for latency, amplitude and conduction
velocity were stored in an Access database. Skin
temperatures were measured electronically at the palmar
wrist and dorsum of the foot before the onset of nerve
conduction testing and the measurements corrected at
the time of analysis using standard formulae [41]. The
filter setting for motor nerve conduction was 3 Hz for
low frequency and 10 kHz for high frequency. The
sensitivity and sweep was set at 5 mV and 50 ms
respectively. The abductor digiti minimi, abductor
pollicis brevis and extensor digitorum brevis muscles
were used to test the ulnar, median and peroneal motor
nerves respectively. Stimulation was performed at two
sites. The distal stimulation was 6 cm proximal to the
active recording electrode for all nerves. The proximal
stimulation site was 10 cm above medial epicondyle for
ulnar, antecubital fossa for median and behind the
fibular head for the peroneal motor nerve. The velocity
was calculated between the distal and proximal stimula-
tion sites using the onset of the evoked CMAPs,
amplitudes were measured from negative to positive peak.
Sensory nerve function.
4. Sensory testing was done with a standard set of
Semmes-Weinstein monofilaments (MF) [42]
The monofilaments used were 200 mg, 2 g, 4 g, 10 g
and 300 g. Normal thresholds were 200 mg for the hand
and 2 g for the foot (excluding the heel) [43]. The test
sites and scoring methods have been described elsewhere
[39].
5. Sensory nerve conduction measurements
(SNC)
SNAP parameters were measured bilaterally on 4 nerves
(radial cutaneous, ulnar, median and sural) using the
same equipment and procedures as described under
MNC. Monopolar surface recording electrodes and
bipolar hand held stimulating electrodes were used to
obtain the sensory nerve action potentials (SNAP). All
the sensory nerve conduction testing were antidromic.
The filter setting was 20 Hz for low frequency and
2 kHz for high frequency. The sensitivity and sweep was
set at 10 mV and 20 ms respectively. Responses were
averaged up to 6 times, if needed. Ulnar and median
SNAPs were registered over digit 5 and digit 2,
respectively. The radial sensory potentials were regis-
tered at the base of thumb and the sural behind the
lateral malleolus. Electrical stimulation was performed
over the nerve 12 cm proximal from the recording site
for all tests. The onset of the evoked SNAP was used to
calculate velocities; amplitudes were measured from the
negative to positive peak.
6. Vibration Perception Threshold (VPT) testing
VPTs were testing with a Vibrameter IIH, Somedic,
Sweden. Application force-controlled measurements of
the VPTs in microns of skin displacement, using the
method of limits (slowly increasing vibration amplitude,
until the person tested indicates that (s)he can feel the
vibration) were made. The test sites were the thenar and
hypothenar eminences (soft tissue), for testing the
median and ulnar nerve, respectively, the dorsal first
webspace for the radial cutaneous nerve, the plantar
surface of the big toe (posterior tibial) and the mid-lateral
border of the foot (sural). All tests were done bilaterally.
7. Thermal threshold testing
Thermal thresholds were evaluated using a Thermal
Sensory Analyzer (TSA IIH, MEDOC, Israel). Warm
and cold detection thresholds (WDT/CDT) were
measured relative to a baseline thermode temperature
of 32uC, using an algorithm called the ‘method of levels’
[44]. 10uC and 50uC were set as measurable limits of
cold and warm perception, respectively. Test sites were
the same as for vibrometry, described above.
Analysis
The thresholds for impairment were determined from norma-
tive studies done as part of this project. From these, age, sex and
centre-specific normal thresholds were calculated as the 97.5th
centile of the log-transformed data. Each measured value in
individual patients was compared with the appropriate age, sex
and centre-specific normal threshold (back-transformed to real
values). No significant differences were found between left and
right extremities, so assessments were pooled for left and right.
Subjects who developed a new outcome event were matched for
sex, age group, leprosy type and length of available follow-up with
a control who had not developed an outcome event prior to or in
the six months following the ‘outcome event visit’ of the case. E.g.,
if a case had an outcome event at visit 4, then only subjects who
were free of outcome events until visit 10 were eligible as matched
control. However, most analyses were not matched on a one-to-
one basis, but a sub-group of the cases is compared as a group with
their matched control group. With the matching criteria used, it
proved impossible to exclude controls with prior, ‘old’ NFI in one
or more nerves. This resulted in relatively high levels of neural
impairment even in the control group. Therefore, to examine
trends over time, another control group was selected. This
group of 16 subjects was free of clinically detectable NFI (by
MFT and VMT standards) throughout the follow-up period. Data
in the trend graphs examining onset of NFI are compared with
these ‘NFI-free controls’, as well as with the relevant normal
thresholds.
Analysis regarding onset of NFI was done on nerves without
evidence of any old impairment (measured by MFT or VMT).
Nerves of patients receiving steroids for skin reactions were
excluded, even if they developed new NFI, as were nerves biopsied
because of an outcome event earlier during the follow-up. For NC
parameters, non-conducting nerves were included in the predictive
value analyses, because they are often also detected as impaired on
other tests.
Prevalence estimates are given as percentages. The significance
of associations between categorical variables was tested using the
Chi-squared or Fisher’s exact test. Differences between propor-
tions were tested with the z-test for differences between
proportions. The term ‘concordance’ is used to describe the direct
agreement between the results of two tests in terms of ‘impaired’
and ‘not impaired’. Analyses were performed using Stata
software, v.9.
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www.plosntds.org 3 April 2008 | Volume 2 | Issue 4 | e212
Ethical considerations
The study was approved by the ethics committee of the Central
JALMA Institute for Leprosy, a major leprosy research centre of
the Indian Council for Medical Research. No financial incentives
were given to participants. Informed written consent was obtained
from individual study subjects before inclusion in the study, using a
standard consent form. Further details are available elsewhere
[39].
Results
Three hundred and three subjects were enrolled in the study.
Their mean age was 32.8 years (range 12–60). Over 50% had
grade 1 or 2 impairment and 36% were smear-positive. Twenty-
one percent had an average BI of 3 or more and 9.6% had grade 2
(visible) impairment of eyes, hands or feet. Thirty percent reported
a detection delay of ,6 months; 32% between 7–12 months and
the remainder (38%) 13 months or longer. Of the 303 subjects,
115 had a reaction or NFI event at registration, leaving a cohort of
188 for the prospective ‘early detection’ analysis. Of these, 74
developed an outcome event (reaction or NFI) during the two-year
follow-up (39%). For 73 of these cases, a matched control was
found. The characteristics of both groups are shown in Table 1.
They were very similar, except that significantly more cases than
controls had old sensory impairment (SI) at diagnosis (duration .6
months); for old motor impairment (MI) the difference was not
significant.
Nearly 75% of patients with an outcome event had their first
event within the first six months. Eleven had an event during the
second half of the first year (15%); the remaining 8 occurred
during the second or even third year. NFI without skin signs of
reaction was the most frequent outcome event (23% of the cohort;
60% of all events). T1R came second with 10% (Table 1). SI was
much more frequent than motor impairment (MI; 19% vs. 2.1%).
Isolated MI also occurred in 2.1%.
Comparing nerve function tests
Table 2 shows the relative frequencies of impairment as
detected by the various tests among patients who had an outcome
event (N= 74), compared to the results among the matched
controls. Nerve conduction parameters, particularly SNAP
amplitudes and CMAP velocities, were the most frequently
affected measurements, followed by thermal thresholds, VPTs,
MFs and, lastly, VMTs. Regarding ulnar nerves, SNAP amplitude
was impaired in 42%, CMAP velocity in 43%, WDT in 29%,
CDT in 13%, VPT in 19%, MFT in 15% and VMT in 11%. In
the radial cutaneous nerve, SNAP amplitude was impaired in
60%, WDT in 48%, CDT in 42%, VPT in 24% and MFT in
8.8%. The pattern was not always completely consistent. In the
median nerve, WDTs were more often impaired than NC
parameters, while in the sural nerve, NC was as often impaired
as thermal sensation.
Electrophysiology and QST detected impairment more often
than MFT and VMT (Table 2). In the ulnar nerve, MFs detected
15% impairment, while SNC detected 42%; in the sural nerve,
37% and 69%. VMT detected even less impairment than MFT
(11% vs. 43% for the ulnar and 2.7% vs. 32% for lateral popliteal).
It was striking that there were relatively small differences in
impairment frequency between cases and controls. For some
nerves, these differences were not even statistically significant (e.g.
ulnar MNC velocity 42.5% vs. 33.3%).
Table 3 shows the relationship between duration of onset of
clinically detectable NFI (MFT and VMT) and the duration of
impairment as measured with neurophysiological tests. The
majority of nerves that were impaired by the monofilament test
(both old or new impairment), already had evidence of old
impairment by SNC or WDT (onset .6 months) (e.g. ulnar and
sural nerves 100%). In addition, up to 12% of ulnar and 8% of
sural nerves with normal monofilament tests had new impairment
of SNC latency or amplitude. This was even true for nerves in the
control group. Hardly any of the new impairment detected by
SNC was detected by MFT (ulnar 7.7%; median 9%, RC 0%),
except in the sural (43%). For WDT these figures were only
slightly better (ulnar 29%, median 10%, RC 0%, PT 46% and
sural 23%). MFT and CDT and VPT gave better concordance for
new impairment detection, although there was more new MFT
impairment detected that was not picked up by CDT or VPT.
Most of the new CDT and VPT impairment in the arms was not
picked up by MFT (as old or new).
Of the old NC and thermal sensory impairment, some was also
detected as old by MFT (e.g. ulnar amplitude 27%; sural
amplitude 50%); however, a substantial proportion was detected
as new MFT impairment (ulnar 22%; sural 11%) or was not
detected at all (ulnar 51%; sural 39%). NC and thermal testing
(particularly WDT in the arms) picked up most nerves with new
impairment among the control group (up to 21% for WDT in the
radial cutaneous nerve).
A similar pattern was seen when comparing impairment
detected by MNC and VMT (Table 4), although numbers were
much smaller. There were few instances of new loss detected by
VMT, the majority of which showed abnormal MNC parameters
more than 6 months earlier or at the time of diagnosis. None of the
new motor impairment detected by MNC was detected by VMT.
Only some old MNC impairment was detected as new (ulnar 12%;
lateral popliteal 10%).
The ability of the various tests to predict a MFT outcome is
shown in Table 5. Because of the small number of outcome events
in different types of nerves, we have pooled all sensory nerves,
except for the posterior nerve, which had a sufficient number of
events on its own. Specificity and negative predictive values (NPV)
were high. Positive predictive values (PPV) were low for all tests.
This is because almost all nerves that developed monofilament
impairment already had old impairment by other parameters.
PPVs were highest for the nerves in the legs, reaching close to 40%
for WDT at 8 weeks prior to the MFT event. Closer to the event,
PPVs were higher for cold detection, reflecting changes in CDT in
the weeks prior to changes detected by MFT.
Comparing nerves
Sensory impairment frequencies varied considerably between
nerves (Table 2). MFT impairment frequencies in these nerves
were 14.9% in the ulnar, 8.8% in the median and RC, 47% in the
PT and 37% in the sural nerve. SNC impairment also varied and
was most frequent in the radial cutaneous and sural nerves (e.g.,
amplitude: ulnar 42%, RC 60% and sural 69%). For WDT
impairment, these figures were 29%, 48% and 67%, respectively.
CMAP velocity was impaired in 43% of ulnar, 25% of median and
29% of lateral popliteal nerves.
Trends over time
Figure 1 shows SNC results over time in sural nerves of subjects
for whom at least 3 advance visits were available and in whom new
sural MFT impairment was diagnosed (at time ‘zero’). The graphs
show the median amplitude values of cases with MFT impairment
and controls, as well as the normal threshold. While median values
of control nerves were in the normal range, no sensory amplitudes
could be recorded from any of the ‘case nerves’ even 3 visits before
deterioration in function was detected by MFT test. The pattern
Early Diagnosis of Neuropathy in Leprosy
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Table 1. Characteristics and outcome details of the subjects in the incidence cohort of the INFIR Cohort Study (N= 188).
Variable Cases# (N=74) Controls (N=73) p - value*
Frequency Percentage Frequency Percentage
Sex
Men 52 70.3 51 69.9 0.96
Women 22 29.7 22 30.1
Age group
12–20 7 9.4 13 17.8 0.035
21–30 21 28.4 27 37.0
31–40 17 23.0 20 27.4
41–50 25 33.8 9 12.3
.50 4 5.4 4 5.5
Classification
BT 46 62.1 43 58.9 0.12
BT (PN)** 3 4.1 0 0
BL (PN)*** 0 0 4 5.5
BL 18 24.3 17 23.3
LL 7 9.5 9 12.3
Smear BI****
Positive 23 31.1 24 32.9 0.82
Negative 51 68.9 49 67.1
Old SI^
Yes 37 50.0 20 27.4 0.0049
No 37 50.0 53 72.6
Old MI^^
Yes 9 12.2 4 5.5 0.15
No 65 87.8 69 94.5
N= 188^^^
Type 1 reaction
Skin only 12 6.4
Skin+neuritis 3 1.6
Skin+NFI 2 1.1
Skin+NFI+neuritis 2 1.1
All T1R 19 10.1
Type 2 reaction
Skin only 3 1.6
Skin+neuritis 1 0.5
Skin+NFI 1 0.5
Skin+NFI+neuritis 0
All T2R 5 2.7
NFI only
MI+SI 4 2.1
MI only 4 2.1
SI only 36 19.1
All NFI 44 23.4
Neuritis only
no NFI 1 0.5
With NFI 5 2.7
All neuritis 6 3.2
Any event 74 39.4
# cases = patients with sensory impairment by monofilament test, motor impairment by VMT or a Type 1 or 2 leprosy reaction; * = Chi-square test; ** = Pure neuritic, BT
histology; *** = Pure neuritic, BL histology; **** = Bacteriological index of the skin smear at diagnosis; ^ = Sensory impairment; ^^ =Motor impairment; ^^^ = the cumulative
incidence of reactions and nerve function impairment (NFI) used the whole cohort as denominator (N= 188).
doi:10.1371/journal.pntd.0000212.t001
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was similar in other nerves, but there were too few impaired nerves
sufficient advance visits for meaningful analysis. CMAP amplitude
values of ulnar case nerves decreased sharply from 8 weeks prior to
the event (Figure 2).
WDT impairment also often started 12 weeks or more before
the MFT impairment became detectable (Figure 3). Control nerve
thresholds were just below or around the normal cut-off.
Impairment in cold and vibration perception generally occurred
later (closer to the time of the MFT event) than was the case with
SNC and WDT impairment (data not shown).
CDTs decreased slightly at the time of a MFT event, but the
effect was not very pronounced, except in the radial cutaneous and
sural nerves (not shown). In the latter two, the median threshold
dropped 4.6 and 5.8uC four weeks before the event and another 9
and 8.1uC at the time of the event. No downward trend was
observed in the control nerves.
VPTs were generally within the normal range, right up to a
MFT impairment event (not shown). An increase in median
threshold occurred in all nerves at the event, but this was
statistically significant only for the ulnar nerve (p=0.047,
Wilcoxon test). The trend pattern in the three dynamometry
measures was variable, but no downward trend was observed until
4 weeks prior to a VMT event in the hand (not shown). At the time
of the outcome event, a clear decrease was observed in grip
strength, similar to the one seen in VMT sum score. No trend was
obvious in either key-pinch or pulp-to-pulp pinch strengths (not
shown).
Discussion
This study investigated which test or combination of tests would
be the earliest in detecting changes in nerve function prior to a
clinical nerve damage event. This is the first study to examine this
question prospectively, using instruments that assess thick
myelinated, thin myelinated, as well as unmyelinated fibre systems.
The results have been very revealing. Electrophysiology and
QST detected far more sensory and motor neuropathy in this
cohort of leprosy patients than the standard tests, MFT and VMT.
Table 4. Cross tabulation of motor impairment, compared to age and sex-specific normal thresholds, between the VMT and
various motor nerve conduction tests used in the INFIR Cohort Study at the time of the incident event in the respective nerves.
Test* Uln Med LP
Cases Controls Cases Controls Cases Controls
No Old New No Old No Old New No Old No Old New No Old
VMT Imp. status 132 10 6 141 5 144 1 1 146 144 4 145 1
% 89.1 6.8 4.1 96.6 3.4 98.6 0.7 0.7 100 97.3 2.7 99.3 0.7
MNC w/a** (N)^ 122 6 4 124 5 128 1 138 128 3 127 1
No conduction 1 2 2 1 1 1 12 2 6 1
% 0.8 33 1.6 20 0.8 0.7 9.4 67 4.7 100
Latency old* 1 3 0 2 2 11 1 7 1
% 0.9 60 67 1.6 9.2 33 5.7 100
Latency new* 4 6 2 4 6 1 5
% 3.5 5.0 1.6 2.9 5.0 33 4.0
Amplitude old* 1 4 3 3 5 2 24 3 18 1
% 0.9 67 2.5 100 4.1 1.5 19 100 15 100
Amplitude new* 7 1 10 7 10 10 6
% 6.1 17 8.3 5.8 7.5 8.0 5.0
e/f** (N) 117 6 4 123 5 125 1 125 128 4 130 1
No conduction 1 2 1 1 12 3 6 1
% 0.9 33 20 0.8 9.4 75 4.6 100
Velocity old* 21 4 2 16 6 1 12 2 11 1
% 20 67 67 15 5.0 0.8 9.9 67 9.0 100
Velocity new* 16 8 1 19 1 14 15 8
% 15 7.3 33 16 100 12 12 6.6
Amplitude old* 10 5 2 7 3 5 3 26 3 24 1
% 9.4 83 67 5.8 100 4.2 2.5 21 75 19 100
Amplitude new* 7 13 8 9 10 2
% 6.5 11 6.8 7.6 7.9 1.6
Cases are patients with an incident event (sensory impairment by monofilaments, motor impairment by VMT or a Type 1 or 2 leprosy reaction; N = 74); controls are
patients with leprosy, but without an event (N = 73). Frequencies among the controls refer to the same follow-up visit as the incident event of ‘their cases’.
VMT= voluntary muscle test, MNC= sensory nerve conduction; ^ the N represents the denominator for the first parameter listed. However, due to a variety of reasons,
the N was not always exactly the same for each parameter of that same test; * Old = impairment already present at diagnosis; New=new or additional impairment at the
time the patient was diagnosed to have an outcome event; ** w/a = at the wrist or ankle; e/f = at the elbow or fibula head.
doi:10.1371/journal.pntd.0000212.t004
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Sensory nerve conduction (particularly amplitude) and warm
perception testing proved by far the most sensitive in picking up
sub-clinical neuropathy ahead of a deficit becoming detectable by
MFT. In the ulnar nerve, SNAP amplitudes and WDTs were
abnormal in 42% and 30% of cases, while monofilaments showed
impairment only in 15%. For the sural nerve, these figures were
69%, 67% and 37%, respectively. Even 12 weeks before the onset
of a MFT sensory event, SNC and WDTs were already abnormal
in nerves that would develop a MFT impairment (see Figure 1 and
Figure 3). Because most outcome events occurred in the first few
months following the start of MDT, it proved impossible to trace
back to the onset of warm detection impairment. The same was
true for SNC; both distal latency and amplitude were abnormal at
least 12 weeks before sensory impairment became clinically
evident. This corresponds with findings in earlier cross-sectional
NC studies that a substantial proportion of clinically unaffected
nerves have evidence of sub-clinical neuropathy [19,23,24,26].
Tzourio et al. [45] and Antia et al. [20] found NC abnormalities in
patients with very early forms of leprosy, but did not relate this to
the occurrence of subsequent NFI. Previous workers have found
that SNAP amplitudes were more severely affected than latencies
or velocities [24], and may indicate early nerve involvement. Of
the two thermal modalities, warm perception was affected much
earlier than cold perception, although the predictive value of both
tests was very similar. This in contrast to diabetic neuropathy,
which affects cold sensation more than warm sensation [31].
In most of the nerves in which a new MFT events occurred
during follow-up, SNC or WDT impairment of long duration was
already present (ulnar 100%, PT 68%, sural 78%; see Table 3).
Very little of the new impairment detected by SNC or WDT was
Figure 1. Trend in sensory amplitude in the sural nerve prior to
a sensory impairment event detected by monofilaments (case
nerves: n=6; control nerves: n=14). ‘Cases’ are nerves with new
sensory impairment by monofilament (MF) test at time ‘0’; ‘controls’ are
nerves without any clinically detectable sensory impairment during
follow-up; P50=median value; normal threshold refers to the specific
parameter tested (here SNC amplitude).
doi:10.1371/journal.pntd.0000212.g001
Figure 2. Trend in CMAP amplitude in the ulnar nerve above
the elbow prior to a motor impairment event detected by VMT
(case nerves: n=5; control nerves: n=14). ‘Cases’ are nerves with
new motor impairment by voluntary muscle test (VMT) at time ‘0’;
‘controls’ are nerves without any clinically detectable sensory or motor
impairment during follow-up; P50=median value; normal threshold
refers to the specific parameter tested (here MNC amplitude).
doi:10.1371/journal.pntd.0000212.g002
Table 5. Predictive value of new impairment detected by quantitative sensory testing and sensory nerve conduction testing in
predicting new impairment by monofilament test at 12, 8 and 4 weeks before the event, in five sensory nerves in the INFIR Cohort
Study.
3rd visit 2nd visit 1st visit Event
Nerve Test* N** Sens Spec PPV NPV Sens Spec PPV NPV Sens Spec PPV NPV Sens Spec PPV NPV
All SNCL 18/611 11 93 4.6 97 17 93 6.8 97 16 90 5.0 97 17 91 5.3 97
sens^
SNCA 18/615 0 93 0 97 0 90 0 97 0 90 0 97 0 92 0 97
WDT 19/669 16 89 3.9 97 33 84 5.5 98 26 78 3.3 97 26 80 3.6 97
CDT 19/669 16 92 5.5 97 22 91 6.7 98 26 87 5.6 98 37 90 9.3 98
VPT 20/699 15 93 6.3 97 11 93 4.0 97 11 93 4.0 97 30 95 14 98
PT*** WDT 37/165 19 87 29 80 29 86 39 80 26 85 34 80 24 89 39 80
PT CDT 36/165 5.4 96 25 79 5.3 94 22 76 16 93 40 79 28 97 71 83
PT VPT 37/174 2.6 93 10 78 11 93 31 78 16 91 32 80 14 95 42 80
Only cases (patients with sensory impairment by monofilaments, motor impairment by VMT or a Type 1 or 2 leprosy reaction) with at least a 12-week follow-up before
occurrence of the event were included. * VPT = vibration perception threshold; WDT=warm detection threshold; CDT = cold detection threshold; SNC= sensory nerve
conduction, L = distal latency, A = amplitude; ** N = number of nerves with an sensory outcome event (monofilament) out of all nerves tested (these numbers varied at
the different time points, because of occasional equipment failure, or because occasionally certain parameters could not be measured; the numbers shown refer to the
number at the time of the outcome event); ^ all sensory nerves pooled, except for the posterior tibial nerve; *** PT = posterior tibial nerve.
doi:10.1371/journal.pntd.0000212.t005
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clinically detected with MFT. In a small proportion of posterior
tibial nerves (23%), new clinical impairment occurred without
evidence of impairment of thermal sensation or vibration sense.
This has been described previously [46,47].
The early changes were less obvious with MNC (Figure 2),
although MNC parameters were frequently impaired (ulnar 32%,
LP 32%). CMAP velocities and amplitudes were lower in most
case nerves than in control nerves at least from 12 weeks before the
event, but they were above or near the normal threshold in about
half of the nerves. While vibrometry trends tended towards
impairment at the time of an event, all nerves in our control
sample stayed within the normal range. With dynamometry, only
grip strength deteriorated towards the time of a VMT outcome
event.
These data show that sensory and motor impairment detected
by MFT and VMT are only the tip of an ‘iceberg of neuropathy’
in leprosy. Even in patients with no clinical signs of reaction, no
nerve tenderness, no clinically evident NFI (detectable by MFT or
VMT), or symptoms of nerve pain, definite evidence of silent
sensory and/or motor neuropathy was found (ulnar up to 26%,
RC 50%, and sural 47%). Early detection of such neuropathy is
possible with a combination of SNC and WDT testing, but the
prognostic benefits of this still need to be determined through a
controlled treatment trial. SNC is technically difficult to test in
many leprosy endemic countries, but simpler techniques, using
cheaper equipment, are being developed (Wilder-Smith, personal
communication). WDT measurement was technically very easy
with the user-friendly TSA II equipment, but the machine is
expensive and required regular maintenance and replacement of
parts. A simpler, low(er)-cost machine is also being developed. A
major practical problem with these tests is that some environ-
mental temperature control is required. With SNC, changes in
outside temperature can be accounted for by adjustment of the
results. The TSA II required operating temperatures of less than
26uC, so an air-conditioned environment would be essential in
most leprosy endemic countries.
In this study, vibrometry and dynamometry did not detect
sensory and motor neuropathy before MFT and VMT. The
former has been shown to be useful in monitoring diabetic
neuropathy and in early detection of toxic neuropathies, such as
cisplatin-induced sensory neuropathy [48–50]. Perhaps the testing
technique – applying the vibration stimulus to soft tissue rather
than superficial bony structures – accounts for the difference. The
technique was chosen because, in leprosy, deep sensation is often
intact when skin sensation is already impaired. Another possible
reason is the relative large diameter of the vibrometer probe,
which stimulates an area of several square centimetres. Because
leprosy neuropathy is not homogeneous, remaining intact sensory
receptors may detect the stimulus, giving the impression of normal
vibration sense.
A high prevalence of impairment was found in the radial
cutaneous and sural nerves (up to 60% and 69%, respectively,
depending on the parameter tested). For sensory amplitude and
warm sensation, the sural was the most frequently affected of all
nerves. In current clinical practice, these two nerves are often not
examined. Our results, as well as those of the baseline analysis of
the INFIR Cohort Study [51], indicate that examination of these
nerves could be important in diagnosing leprosy and monitoring
nerve damage. Examining both nerves using monofilaments is easy
and quick to do.
Although sensory and motor neuropathy was much more
widespread than the NFI detected by MFT and VMT, these tests
were still validated by the current results. MFT results correlated
well with the overall level of neural impairment and changes in
MFT scores mirrored changes in one or more neurophysiological
parameters, particularly cold perception and VPTs. Monofila-
ments have been widely promoted as accurate and reliable
instruments for monitoring sensory neuropathy, particularly in
leprosy and diabetes [25,52–58]. Samant et al. found that a
combination of MFT and nerve palpation detected nearly as much
‘nerve involvement’ (33%) as did SNC testing on its own (41%),
but it was not clear from the report whether this concerned the
same nerves nor whether this concerned old or new impairment
[26]. Breger compared MFT and SNC and found 81%
concordance between MFT results and SNAP amplitudes in a
sample of 142 ulnar and median nerves [47]. In the present study
this particular concordance was 74% for the ulnar and 76% for
the median nerve at the time of the outcome event (data not
shown). Therefore, graded monofilaments and manual voluntary
muscle testing do reflect overall nerve function at a given point in
time, but, compared to nerve conduction or warm perception,
monofilament testing underestimated the extent of the damage
and detected it late. Research into neuropathy in leprosy or the
treatment of such neuropathy should include SNC and/or WDT
testing to detect and monitor sensory impairment not detectable
by monofilaments. Further studies should investigate the prognos-
tic value of early diagnosis and treatment of sensory impairment
detected with nerve conduction and thermal testing.
Conclusions
1. Leprosy neuropathy is much more extensive than indicated
when MFT and VMT were used.
2. SNC measurements, in particular SNAP amplitude, and warm
perception are the most frequently and earliest affected
parameters. These are the most promising tests for early
detection of leprosy neuropathy.
3. SNC parameters and WDTs often become abnormal 12 weeks
or more before NFI can be diagnosed by MFT.
4. Changes in the MFT and VMT scores mirror physiological
changes in affected nerves, confirming their validity as
screening tools.
5. The radial cutaneous and sural nerves are affected frequently.
Routine inclusion of these in assessment will help in the
monitoring of leprosy nerve damage.
Figure 3. Trend in WDTs in the sural nerve prior to a sensory
impairment event detected by monofilaments (case nerves:
n=8; control nerves: n=16). ‘Cases’ are nerves with new sensory
impairment by monofilament (MF) test at time ‘0’; ‘controls’ are nerves
without any clinically detectable sensory impairment during follow-up;
P50=median value; normal threshold refers to the specific parameter
tested (here warm detection thresholds).
doi:10.1371/journal.pntd.0000212.g003
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